الصفحة الرئيسية>>Signaling Pathways>> Others>>BTYNB IMP1 Inhibitor

BTYNB IMP1 Inhibitor

رقم الكتالوجGC42986

مثبط BTYNB IMP1 هو مثبط قوي وانتقائي لربط IMP1 بـ c-Myc mRNA (IC50 = 5 μ ؛ M). يُظهر مثبط BTYNB IMP1 الانتقائية والفعالية ضد سلالات الخلايا السرطانية IMP1-postive. يمكن استخدام مثبط BTYNB IMP1 في أبحاث السرطان.

Products are for research use only. Not for human use. We do not sell to patients.

BTYNB IMP1 Inhibitor التركيب الكيميائي

Cas No.: 304456-62-0

الحجم السعر المخزون الكميّة
1mg
20٫00
متوفر
5mg
90٫00
متوفر
10mg
153٫00
متوفر
25mg
315٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

BTYNB IMP1 inhibitor is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). [1] It downregulates c-Myc and β-TrCP1 mRNA and reduces IMP1 protein levels in SK-MEL-2 and IGROV-1 cells. BTYNB IMP1 inhibits proliferation of IMP1-positive ES-2, IGROV-1, and SK-MEL-2 cells (IC50s = 2.3, 3.6, and 4.5 μM, respectively) but not IMP1-negative BG-1 and T47D-KBluc cells (IC50s = >50 μM for both). It also inhibits anchorage-independent growth of SK-MEL-2 cells when used at a concentration of 10 μM.

Reference:
[1]. Mahapatra, L., Andruska, N., Mao, C., et al. A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation. Transl. Oncol. 10(5), 818-827 (2017).

مراجعات

Review for BTYNB IMP1 Inhibitor

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BTYNB IMP1 Inhibitor

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.